BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38566204)

  • 1. Investigating the impact of regulatory B cells and regulatory B cell-related genes on bladder cancer progression and immunotherapeutic sensitivity.
    Zhou J; Zhou R; Zhu Y; Deng S; Muhuitijiang B; Li C; Shi X; Zhang L; Tan W
    J Exp Clin Cancer Res; 2024 Apr; 43(1):101. PubMed ID: 38566204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction and experimental validation of a B cell-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer.
    Zhou R; Zhou J; Muhuitijiang B; Zeng X; Tan W
    Aging (Albany NY); 2023 Jun; 15(12):5355-5380. PubMed ID: 37379131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing and experimental validating a B cell exhaustion-related gene signature to assess prognosis and immunotherapeutic response in bladder cancer.
    Zhou R; Zhou J; Deng S; Zhu Y; Muhuitijiang B; Wu J; Tan W
    Gene; 2024 Jun; 927():148634. PubMed ID: 38848880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
    Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
    Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and experimental validation of a B cell senescence-related gene signature to evaluate prognosis and immunotherapeutic sensitivity in bladder cancer.
    Zhou R; Zhou J; Muhuitijiang B; Tan W
    Funct Integr Genomics; 2022 Dec; 23(1):3. PubMed ID: 36527532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer.
    Cao M; Cao Y; Xue S; Zhang Q; Zhang H; Xue W
    Altern Ther Health Med; 2024 Apr; 30(4):130-138. PubMed ID: 38518167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
    Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S
    Front Immunol; 2023; 14():1253586. PubMed ID: 37790935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and experimental validation of a folate metabolism-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer.
    Liu X; Chen C; Xu P; Chen B; Xu A; Liu C
    Funct Integr Genomics; 2023 Sep; 23(4):291. PubMed ID: 37676513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a novel signature based on unfolded protein response-related gene for predicting prognosis in bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Hum Genomics; 2021 Dec; 15(1):73. PubMed ID: 34930465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer.
    Chen X; Qin Z; Zhu X; Wang L; Li C; Wang H
    Sci Rep; 2023 Dec; 13(1):21816. PubMed ID: 38071230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and experimental validation of a macrophage cell senescence-related gene signature to evaluate the prognosis, immunotherapeutic sensitivity, and chemotherapy response in bladder cancer.
    Jiang Q; Zhou J; Chen Q; Huang Y; Yang C; Liu C
    Funct Integr Genomics; 2023 Jul; 23(3):228. PubMed ID: 37423913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and validation of an immune signature associated with EMT and metabolic reprogramming for predicting prognosis and drug response in bladder cancer.
    Zhang Z; Yu Y; Li P; Wang M; Jiao W; Liang Y; Niu H
    Front Immunol; 2022; 13():954616. PubMed ID: 35958586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
    J Exp Clin Cancer Res; ; . PubMed ID: 35581606
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.